The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms
Official Title: Aprepitant Versus Hydroxyzine in Association With Cytoreductive Treatments for Patients With Myeloproliferative Neoplasia Suffering From Persistent Aquagenic Pruritus.
Study ID: NCT03808805
Brief Summary: Phase 3, randomized prospective study, double blind-double placebo, testing oral therapies APREPITANT versus HYDROXYZINE in patients followed for myeloproliferative neoplasms and suffering of persistent aquagenic pruritus.
Detailed Description: Identification of patients with myeloproliferative neoplasms and aquagenic pruritus. Evaluation of the intensity of the aquagenic pruritus. Patients with value \>5/10 on the VAS (Visual Analogue Scale ) are proposed to participate to the protocole. Randomization between the two treatments. Duration of the treatment : 14 days. Regular evaluation of efficacity of the drugs (questionnaires). Evaluations will stop 2 months after the last intake. Blood samples will be collected before and after the intakes to study cytokine and neuropeptide levels.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
CHRU de Brest - Hôpital Morvan, Brest, Brest Cedex, France
CHU d'Angers, Angers, , France
CHU de Caen, Caen, , France
Centre Hospitalier de Douarnenez, Douarnenez, , France
CHU Grenoble Alpes, Grenoble, , France
Centre Léon Bérard, Lyon, , France
Centre Hospitalier des Pays de Morlaix, Morlaix, , France
CHU de Nantes, Nantes, , France
Centre Hospitalier de Cornouaille, Quimper, , France
Hôpital Pontchaillou, Rennes, , France
Hôpital Yves Le Foll, Saint-Brieuc, , France
Name: Jean-Christophe IANOTTO, MD, PhD
Affiliation: Hématologie Clinique-Institut de Cancéro-Hématologie
Role: PRINCIPAL_INVESTIGATOR